Search results for "TC"

showing 10 items of 9993 documents

The Factorial Structure of the Outcome Questionnaire-45: A Study with an Italian Sample.

2008

In this article, the authors study the factorial structure of the Italian translation of the Outcome Questionnaire 45 (OQ-45) in a sample of college students (n = 522) and psychiatric outpatients (n = 301). The relative goodness of fit of six competing models of the OQ-45 was examined using confirmatory factor analysis (CFA). Specifically, the study examined the relative fit of the most frequently presented models in the literature and three alternative models. Results of the CFA provided support for the four factor bi-level solution, suggesting that the OQ-45 is a multidimensional instrument that contains one general factor and multiple unique subscale factors.

AdultMaleOQ-45 confirmatory factor analysisFactorialPsychometricsPsychometricsMental DisordersTreatment outcomeReproducibility of ResultsSample (statistics)Factor structureOutcome (probability)Confirmatory factor analysisPsychotherapyClinical PsychologyTreatment OutcomeItalyGoodness of fitSurveys and QuestionnairesStatisticsHumansFemaleFactor Analysis StatisticalStudentsPsychology
researchProduct

Psychological and behavioural factors associated with long-term weight maintenance after a multidisciplinary treatment of uncomplicated obesity

2013

Obesity is a multifactorial syndrome and the likelihood of success of a medical nutritional treatment (MNT) over the long term is low. As psychological and behavioural factors have an important role in both pathogenesis and the treatment of obesity, these issues were investigated in individuals with obesity who reported a long-term success or a failure in terms of weight loss following a MNT. Eighty-eight individuals of an original cohort of 251 subjects were re-evaluated 10 years after a MNT with cognitive-behavioural approach for uncomplicated obesity. Fifty-three participants were classified as failure (body weight change ≥0.5 kg) and 35 as a success (10-year body weight change <0.5 kg) …

AdultMaleObesity Diet Quality of life Depression Shape concern DiscomfortAdolescentDiet ReducingHospital Anxiety and Depression ScaleWeight lossSurveys and QuestionnairesWeight LossBody ImagemedicineHumansObesityAgedCognitive Behavioral TherapyBinge eatingFeeding BehaviorMiddle Agedmedicine.diseaseObesitySelf ConceptPsychiatry and Mental healthClinical PsychologyDistressTreatment OutcomeQuality of LifeFemalemedicine.symptomBinge Eating ScalePsychologyAttitude to HealthPsychopathologyClinical psychologyDietingEating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity
researchProduct

A novel approach to challenging OCD related beliefs using a mobile-app: An exploratory study

2017

Abstract Background and objectives According to cognitive models, obsessive compulsive symptoms result from catastrophic misinterpretations of commonly occurring intrusive experiences and the use of counterproductive strategies to manage them. Obsessive Compulsive Disorder (OCD) related beliefs such as inflated responsibility, importance of thoughts and perfectionism increases the likelihood of such misinterpretations. Consistent with a growing body of literature supporting the usefulness of mobile delivered technologies in fostering cognitive behavior change, the present study assessed the effectiveness of a novel cognitive training exercise designed to challenge OCD-related beliefs. This …

AdultMaleObsessive-Compulsive Disorder050103 clinical psychologymedicine.medical_treatmentExperimental and Cognitive Psychologymedicine.disease_causeRelapse preventionbehavioral disciplines and activitiesYoung Adult03 medical and health sciences0302 clinical medicineArts and Humanities (miscellaneous)Outcome Assessment Health Caremental disordersmedicineHumans0501 psychology and cognitive sciencesObsessive-compulsive disorder (OCD)Cognitive Behavioral Therapy05 social sciencesBehavior changeCognitionPerfectionism (psychology)medicine.diseaseMobile ApplicationsTelemedicinehumanitiesCognitive training030227 psychiatryPsychiatry and Mental healthClinical PsychologyMoodCognitive therapyFemalePsychologyClinical psychologyJournal of Behavior Therapy and Experimental Psychiatry
researchProduct

Cognitive therapy for autogenous and reactive obsessions: Clinical and cognitive outcomes at post-treatment and 1-year follow-up

2009

This study provides data about the differential effectiveness of cognitive therapy (CT) for obsessive-compulsive disorder (OCD) symptom presentation. Two OCD manifestations, autogenous and reactive, are considered. Seventy OCD patients started CT; 81.40% completed it and 72.85% were available 1 year later. Fifteen of the 57 treatment completers had autogenous obsessions, whereas 33 had reactive obsessions. Nine patients had both obsession modalities. Reactive patients were more severe, as they scored higher on thought suppression and on the dysfunctional beliefs of intolerance to uncertainty and perfectionism. Autogenous patients scored higher on the over-importance of thoughts beliefs. Alt…

AdultMaleObsessive-Compulsive DisorderPediatricsmedicine.medical_specialtymedicine.medical_treatmentCulture1 year follow upDysfunctional familymedicine.disease_causeSeverity of Illness IndexSex FactorsSurveys and QuestionnairesSeverity of illnessmedicineHumansPsychiatric Status Rating ScalesAnalysis of VarianceCognitive Behavioral TherapyCognitionThought suppressionPerfectionism (psychology)Middle AgedhumanitiesCognitive behavioral therapyPsychiatry and Mental healthClinical PsychologyTreatment OutcomeSocioeconomic FactorsCognitive therapyFemaleObsessive BehaviorPsychologyFollow-Up StudiesClinical psychologyJournal of Anxiety Disorders
researchProduct

Group Versus Individual Cognitive Treatment for Obsessive-Compulsive Disorder: Changes in Severity at Post-Treatment and One-Year Follow-up

2009

Background: Very few studies have compared the efficacy of individual and group cognitive behaviour therapy (CBT) for the treatment of Obsessive-Compulsive Disorder (OCD) by taking into consideration the change in OCD severity in both the short and long term. Aims: To conduct an open trial of individual versus group CBT for OCD, comparing the clinical and statistically significant changes in severity both at post-treatment and one year later. Method: Forty-two OCD subjects were assigned to individual (n = 18) or group CBT (n = 24, in four groups). Sixteen and 22 subjects completed the treatment in the individual and group conditions, respectively. The Yale-Brown Obsessive Compulsive Scale w…

AdultMaleObsessive-Compulsive Disordermedicine.medical_specialtyTime FactorsOne year follow upmedicine.medical_treatmentSeverity of Illness Indexbehavioral disciplines and activitiesGroup psychotherapyObsessive compulsivemental disordersmedicineHumansCognitive Behavioral TherapyCognitionGeneral Medicinemedicine.diseaseCognitive behaviour therapyDiagnostic and Statistical Manual of Mental DisordersClinical PsychologyTreatment Outcomenervous systemPsychotherapy GroupCognitive therapyPhysical therapyFemalePost treatmentPsychologyAnxiety disorderFollow-Up StudiesClinical psychologyBehavioural and Cognitive Psychotherapy
researchProduct

Once-Daily Oral Levofloxacin Monotherapy versus Piperacillin/Tazobactam Three Times a Day: A Randomized Controlled Multicenter Trial in Patients with…

2004

A prospective, randomized, controlled multicenter trial was performed to evaluate the efficacy and safety of once-daily oral monotherapy with 500 mg levofloxacin in comparison with 4.5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia. Low risk was defined by oral temperatureor = 38.5 degrees C on one occasion oror = 38.0 degrees C twice within 24 hours and granulocytopeniaor = 500/microL for less than 10 days. The primary end point was defined as defervescence after 72 hours followed by at least 7 afebrile days. Secondary end points were overall response, time to defervescence, survival on day 30, and toxicity. Thirty-four episodes were included. Fever o…

AdultMaleOfloxacinTazobactammedicine.medical_specialtyNeutropeniaFeverAdministration OralPenicillanic AcidAntineoplastic AgentsLevofloxacinNeutropeniaFever of Unknown OriginTazobactamDrug Administration ScheduleImmunocompromised HostLevofloxacinNeoplasmsInternal medicineMulticenter trialHumansMedicineProspective StudiesAgedAntibacterial agentPiperacillinbusiness.industryBacterial InfectionsHematologyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomePiperacillin/tazobactamDrug Therapy CombinationFemaleDisease SusceptibilitySafetybusinessFebrile neutropeniaPiperacillinmedicine.drugInternational Journal of Hematology
researchProduct

Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

2004

Abstract Purpose: No chemotherapy regimen, including the widely used combination of gemcitabine/cisplatin, confers significantly improved survival over any other in metastatic non-small cell lung cancer (NSCLC); however, the selection of patients according to key genetic characteristics can help to tailor chemotherapy. Ribonucleotide reductase subunit M1 (RRM1) is involved in DNA synthesis and repair and in gemcitabine metabolism, and the excision repair cross-complementing group 1 (ERCC1) gene has been related to cisplatin activity. Experimental Design: Patients were part of a large randomized trial carried out from September 1998 to July 2000, comparing gemcitabine/cisplatin versus gemcit…

AdultMaleOncologyAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsTime FactorsDNA RepairRibonucleoside Diphosphate Reductasemedicine.medical_treatmentAntineoplastic AgentsBiologyVinorelbineDeoxycytidineCarcinoma Non-Small-Cell LungInternal medicineRibonucleotide ReductasesmedicineHumansRNA MessengerLung cancerAgedCisplatinChemotherapyPredictive markerTumor Suppressor ProteinsDNAMiddle AgedEndonucleasesPrognosismedicine.diseaseGemcitabineChemotherapy regimenGemcitabineDNA-Binding ProteinsTreatment OutcomeOncologyFemaleCisplatinERCC1medicine.drugClinical Cancer Research
researchProduct

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell …

2007

On the basis of a preceding phase I study, the current trial explored bendamustine in combination with mitoxantrone and rituximab (BMR) in patients with stage III/IV relapsed or refractory indolent lymphomas and mantle cell lymphoma (MCL) with or without prior rituximab containing chemo-immunotherapy (R-chemo) treatment. Therapy consisted of bendamustine 90 mg/m(2) days 1 + 2, mitoxantrone 10 mg/m(2) day 1, rituximab 375 mg/m(2) day 8. Treatment was repeated on day 29 for a total of four cycles. Between 3 April and 04 July, 57 patients were recruited from 24 participating institutions, 39% of whom had received prior R-chemo therapy. Median age was 66 years (40 - 83). Lymphoma subtypes were …

AdultMaleOncologyBendamustineCancer Researchmedicine.medical_specialtyPathologyPhases of clinical researchLymphoma Mantle-CellAntibodies Monoclonal Murine-DerivedInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBendamustine HydrochlorideHumansLymphoma FollicularSurvival analysisAgedAged 80 and overSalvage TherapyMitoxantronebusiness.industryLymphoma Non-HodgkinRemission InductionAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurvival AnalysisLymphomaClinical trialTreatment OutcomeOncologyNitrogen Mustard CompoundsMonoclonalFemaleRituximabMitoxantroneRituximabbusinessmedicine.drugLeukemia &amp; Lymphoma
researchProduct

Irinotecan (CPT-11) and Mitomycin-C (MMC) as Second-Line Therapy in Advanced Gastric Cancer

2005

Objective The aim of this study was to evaluate the activity and toxicity of a combination regimen of CPT-11 and mitomycin-c as second-line chemotherapy for pretreated patients with advanced, metastatic, or both, gastric adenocarcinoma. Materials and methods Patients with pretreated metastatic disease or early relapsed after adjuvant chemotherapy were enrolled. Entry criteria included histologic/cytologic diagnosis of gastric adenocarcinoma, age 18 to 75 years, performance status > or =70 (Karnofsky scale), bi-dimensionally measurable disease. Patients received CPT-11 and mitomycin-c at the dosage of 150 mg/m2 on days 1 and 15, and 8 mg/m2 on day 1, respectively, every 4 weeks. The disease …

AdultMaleOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaMitomycinmedicine.medical_treatmentSalvage therapyPhases of clinical researchAdenocarcinomaNeutropeniaIrinotecanGastroenterologyDisease-Free SurvivalStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansLife TablesPeritoneal NeoplasmsAgedSalvage TherapyChemotherapyLeukopeniaPerformance statusbusiness.industryLiver NeoplasmsDrug SynergismMiddle Agedmedicine.diseaseSurvival Analysistherapy gastric cancerIrinotecanRegimenTreatment OutcomeItalyOncologyLymphatic MetastasisCamptothecinFemalemedicine.symptombusinessmedicine.drugAmerican Journal of Clinical Oncology
researchProduct

Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer

2005

&lt;i&gt;Background:&lt;/i&gt; Induction chemotherapy followed by surgical resection or definitive radiotherapy for patients affected by stage IIIA N2 bulky non-small cell lung cancer (NSCLC) has been investigated in several trials. &lt;i&gt;Patients and Methods:&lt;/i&gt; In this present study, 52 patients with stage IIIA N2 bulky NSCLC with cytologically or histologically confirmed mediastinal lymph node involvement received paclitaxel 175 mg/mq on day 1, carboplatin AUC 5 on day 1 and gemcitabine 1,000 mg/mq on day 1 and 8 every 3 weeks for three cycles as induction chemotherapy. &lt;i&gt;Results:&lt;/i&gt; Objective response (4 complete remission and 36 partial remission) was achieved i…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.drug_classmedicine.medical_treatmentDeoxycytidineAntimetaboliteDisease-Free SurvivalDrug Administration ScheduleCarboplatinchemistry.chemical_compoundCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerAgedNeoplasm StagingChemotherapybusiness.industryRemission InductionInduction chemotherapyLung cancer Paclitaxel Carboplatin stage III ChemotherapyGeneral MedicineMiddle Agedmedicine.diseaseSurvival AnalysisGemcitabineGemcitabineCarboplatinrespiratory tract diseasesSurgeryRadiation therapyTreatment OutcomeOncologychemistryPaclitaxelChemotherapy AdjuvantFemaleRadiotherapy Adjuvantbusinessmedicine.drug
researchProduct